Kornimate/medical-research-clean huggingface dataset:
role of transposable elements in septic immune aging

Conditions: Sepsis; Sepsis and Septic Shock; Sepsis With Multiple Organ Dysfunction (MOD); Sepsis With Acute Organ Dysfunction; Sepsis, Severe; Sepsis at Intensive Care Unit; Sepsis, Severe Sepsis and Septic Shock; Sepsis, Septic Shock

Summary: the goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. the main questions it aims to answer is: 1. do transposable elements prematurely age the immune systems of patients with sepsis? 2. do transposable elements correlate with increased mortality in patients with sepsis in the icu? 3. do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the icu? participants will have blood drawn from them but will not be subjected to additional interventions.


Eligibility criteria:
inclusion criteria: * age 18 or older * admitted to icu with sepsis (sepsis 3 criteria) * sofa score of at least 2 at time of enrollment exclusion criteria: * patients on organ transplantation immunosuppression * patients with preexisting leukopenia * cancer patients receiving car-t therapy * patients who are under 18 years of age or otherwise deemed pediatric * patients with an ongoing bleeding diathesis (ie: dic, hemorrhagic shock) * patients with a chronic hemoglobin below 7.0 * patients who, prior to their icu admission, are blood transfusion dependent

Keywords: sepsis transposable elements immune aging mortality secondary infections critical care medicine (icu)
the effect of different bed-head angles on the haemodynamic parameters of intensive care patients lying in the supine position

Conditions: Thyroidectomy; Colon Surgery; Cholecystectomy; Inguinal Hernia

Summary: aim: the aim of this study was to examine the effect of different bed-head angles given to patients lying in the supine position in an intensive care unit on the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation. methods: the study was conducted with 50 intensive care patients aged 18 and over in a general surgery intensive care unit in turkey. with each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes.

aim: the aim of this study was to examine the effect of different bed-head angles given to patients lying in the supine position in an intensive care unit on the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation. design: this was a non-randomised quasi-experimental repeated measures study. settings: the study was conducted with 50 intensive care patients aged 18 and over in a general surgery intensive care unit in turkey. methods: with each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes. the data obtained was evaluated using the mann-whitney test, the kruskal wallis test and the bonferroni test.

Eligibility criteria:
inclusion criteria: * participating voluntarily in the study * being aged over 18 years, * having stayed in the general surgery intensive care unit for at least 24 hours, * being monitored for 24 hours, * having a central venous catheter inserted, * having central venous pressure measured. exclusion criteria: * being less than 18 years of age, * not wanting to participate in the study, or during the course of the research, wishing to withdraw from the study, * receiving sedation treatment, * receiving haemodialysis treatment, * having an oxygen saturation value of less than 90%, * being unable to tolerate a 0° prone position (hypovolemic or bradycardic).

Keywords: intensive care units haemodynamic parameters central venous pressure supine position bed-head angle
a study to assess the anti-emetic efficacy of ginger in children and adolescents receiving chemotherapy

Conditions: Nausea; Vomiting

Summary: ginger root powder is found to be significantly effective,when given as an add-on therapy in reducing chemotherapy induced nausea and vomiting in children and adolescents receiving chemotherapy. it is very cost effective and as compared to the other add-on therapy drug like aprepitant.

cisplatin is a chemotherapeutic agent with high emetogenic potential. high doses of cisplatin (120 mg/m2) induces nausea and vomiting in 90 % of patients. more than 60% of patients experience nausea and vomiting even if they are getting the conventional anti emetic medications. children and adolescents with cancer are using complementary and alternative medicine (cam) to relieve symptoms, reduce side effects of treatment, and cope with the emotional aspects of having a life-threatening illness. parental decisions about using cam should be based on studies of efficacy and safety . ginger is already used in traditional folk medicine to treat nausea and vomiting.additionally, ginger's ability to block 5-ht3 receptors and its free-radical scavenging action in the gut suggests that it may be beneficial for reducing both the prevalence and severity of chemotherapy induced nausea and vomiting. ginger is an easily available and cost effective substance in indian scenario; (1gm costs less than one rupees). a dose of 1-2 gm of ginger is found to have favourable effects in reducing the incidence of nausea and vomiting. there are not much side-effects of ginger have been established so far, except mild stomach upset, increased burping and nausea seen in very few patients after the ingestion of ginger. ginger is a widely available,affordable and acceptable natural substance which is to be included as an additional treatment option for chemotherapy induced nausea and vomiting which will significantly improve the health, compliance with treatment and quality of life of patients receiving chemotherapy.

Eligibility criteria:
inclusion criteria: * all patients must have a histologically confirmed diagnosis of osteosarcoma/ malignant fibrohistiocytoma of bone that is currently being treated with chemotherapy with high emetogenic potential chemotherapeutic agent(cisplatin at a dose 120mg/m2 ; adriamycin 75 mg/m2) * age group : 8-21 yrs. * weight : greater than or equal to 20 kg and less than 40 kg in category 1 * weight : greater than or equal to 40 kg and less than 60 kg in category 2 * patients who are willing to participate in study. * patients or their parents who can understand hindi or english. exclusion criteria: * patients of age \ 21 yrs. * weight \< 20 kg and greater than or equal to 40 kg in category 1 * weight \< 40 kg and greater than or equal to 60 kg in category 2 * patients receiving chemotherapy with drugs other than cisplatin. * patients receiving a dosage of chemotherapy with cisplatin\<120 mg/m2.

Keywords: nausea vomiting chemotherapy
ims-treatment and canalis carpi syndrome

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome is a condition in which the median nerve is compressed at the wrist, leading to paresthesias, numbness and muscle weakness in the hand. treatment of the condition often involves surgery. in this study we wish to se if there is an effect of using intramuscular stimulation (ims) to release the tension of nervus medianus in the lower arm. the study will be performed by randomization to ims of musculus pronator teres or a control ("scam ims treatment" to the acupuncture point li11). the two insertion points are approximately 1cm apart in the lower arm.

the most important outcome measure is ultra sound measured diameters for nervus medianus in the carpal tunnel

Eligibility criteria:
inclusion criteria: * canalis carpi syndrome verified by ultrasound and clinically * both genders * age from 18 to 67 exclusion criteria: * negative neurophysiology result. * epilepsy, * heart disease, * rheumatism * unstable angina pectoris, * metal -allergy, * needle- phobia, * infection * hemophilia * cognitive problems
a study of cs1-targeted car-t cells therapy for relapsed multiple myeloma after bcma car-t cells therapy

Conditions: Relapse Multiple Myeloma

Summary: clinical trial for the safety and efficacy of cs1-targeted car-t cells therapy for relapsed multiple myeloma after bcma car-t cells therapy

this is a single arm, open-label, single-center study. this study is indicated for relapsed cs1+ multiple myeloma, the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 50 patients will be enrolled for this trial. primary objective is to explore the safety, main consideration is dose-related safety.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of cs1+ multiple myeloma (mm)： 1. patients with mm relapsed after bcma car-t therapy;or mm with positive cs1 expression and negative bcma expression; 2. relapsed after hematopoietic stem cell transplantation; 3. cases with recurrent positive minimal residual disease; 4. extramedullary leision which is hard to be eradicated by chemotherapy or radiotherapy. 2. anticipated survival time more than 12 weeks; 3. male or female aged 30-75 years; 4. those who voluntarily participated in this trial and provided informed consent. exclusion criteria: subjects with any of the following exclusion criteria were not eligible for this trial: 1. history of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagicdiseases; 2. electrocardiogram shows prolonged qt interval, severe heart diseases such as severe arrhythmia in the past; 3. pregnant (or lactating) women; 4. patients with severe active infections (excluding simple urinary tract infectionand bacterial pharyngitis); 5. active infection of hepatitis b virus or hepatitis c virus; 6. concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving inhaled steroids; 7. previously treated with any car-t cell product or other genetically-modified t cell therapies; 8. creatinine\>2.5mg/dl, or alt / ast \> 3 times of normal amounts, or bilirubin\>2.0 mg/dl; 9. other uncontrolled diseases that were not suitable for this trial; 10. patients with hiv infection; 11. any situations that the investigator believes may increase the risk of patients or interfere with the results of study.

Keywords: multiple myeloma car t-cell therapy cs1
coronary flow reserve and glucometabolic state

Conditions: Acute Myocardial Infarction; Diabetes Mellitus; Prediabetes

Summary: diabetes mellitus is a major risk factor for the development of ischemic heart disease, and patients with diabetes mellitus have a worse outcome following an acute myocardial infarction than non-diabetic patients. furthermore, abnormal glucose metabolism below the diagnostic threshold of diabetes mellitus is also associated with increased risk of death compared to patients with a normal glucose metabolism. the frequency of abnormal glucose metabolism in acute myocardial infarction is high, and approximately 70% of myocardial infarction patients have diabetes mellitus, newly diagnosed diabetes mellitus or impaired glucose tolerance, leaving only 30% with normal glucose metabolism. the increased mortality among patients with acute myocardial infarction and abnormal glucose metabolism seems mainly related to a higher occurrence of congestive heart failure, suggesting that an abnormal glucose metabolism may play an important role among others in endothelial dysfunction, infarct healing and overall left ventricle function. this raises the question, whether patients with acute myocardial infarction and abnormal glucose metabolism have increased frequency of micro- or macrovascular disease or both. coronary flow velocity reserve reflects the patency of the epicardial coronary artery in combination with vasodilator capacity of the microcirculation and may therefore offer a tool for assessment of macro- and microcirculation. this study will focus on the relation between coronary flow velocity reserve estimated by transthoracal doppler echocardiography and mortality, risk for heart failure and left ventricle function after acute myocardial infarction stratified according to glycometabolic state


Eligibility criteria:
inclusion criteria: 1. newly diagnosed first ami based on characteristic clinical symptoms and/or electrocardiographic signs of ami and troponin t or i or ck-mb over diagnostic limits for ami 2. referral for coronary arteriography based on the actual myocardial infarction 3. written informed consent exclusion criteria: 1. previous myocardial infarction 2. asthma bronchiale 3. 2 or/and 3 degree atrio-ventricular block and paced rhythm 4. mental state that makes the patient unavailable in attending the study 5. use of dipyridamol 6. sick sinus syndrome

Keywords: coronary flow reserve diabetes mellitus acute myocardial infarction transthoracic echocardiography
x-ray verified accuracy of the progav verification instrument

Conditions: Hydrocephalus Shunt (proGAV) Requiring Adjustment

Summary: this study is to verify the use of a hand held tool to verify the new setting of a hydrocephalus shunt (progav). this tool would be used in place of an xray of the patient's head, which is how settings are verified currently.


Eligibility criteria:
inclusion criteria: * implanted with progav requiring adjustment implant must be palpable under the skin exclusion criteria: * unwilling to consent implanted within 7 days of inclusion visit

Keywords: hydrocephalus shunt progav
let it out (lio) and covid19: testing an online emotional disclosure-based intervention during the covid19 pandemic

Conditions: COVID19

Summary: a randomised controlled trial designed to test whether an online expressive writing intervention (lio-c) can reduce distress for english-speaking adults during the global covid19 pandemic. hypothesis: lio-c will improve distress (as measured by k10) in adults at 1 week post-intervention compared to a neutral writing control during the covid19 pandemic.

the world is currently experiencing unprecedented challenges caused by the global coronavirus (covid19) pandemic. many countries are enforcing measures to restrict movement of people to reduce the spread of the outbreak, including lock-downs, social distancing and self-isolation. these methods, although necessary to slow the spread of disease, will have negative effects on psychological well-being of large populations. shortage of health care professionals and measures to restrict interpersonal contact means facilitated psychological interventions will not be feasible for many, at least during the height of the pandemic. there is therefore a need for self-directed psychological interventions that can be practically and quickly implemented online. emotional disclosure-based therapies, such as expressive writing (ew), hold potential as low-cost, easy to implement means of support, with minimal requirement for facilitation. in its original format, ew involved writing daily for 15-20 minutes for 3-4 days about a traumatic event. since its development, it has been adapted in many ways, including writing about positive events and writing about stress from a compassionate stance. there is evidence that such interventions can provide significant psychological and physical benefits in healthy populations and reduce the effects of natural disasters on health and well-being. however, to our knowledge this form of psychological intervention has not been tested during a rapidly evolving crisis or pandemic. the aim of this study is to test whether an online self-compassion and ew based intervention (lio-c) can reduce the negative effects of the covid19 pandemic on health and well-being. the intervention is based on an existing intervention, lio, that we previously developed for use in advanced disease populations, in collaboration with clinical and health psychologists, and patient and public representatives. for this study, we have adapted the intervention for people living through the current covid19 pandemic by altering the writing prompts, and translating the intervention to an online hub. as this is an unfacilitated intervention, the instructions involve writing from a compassionate stance to minimise any potential short term negative effects associated with writing about difficult experiences.

Eligibility criteria:
inclusion criteria: * english speaking adults over the age of 18 * able to read and write clearly in english exclusion criteria: * none

Keywords: covid19 coronavirus
effect of h. pylori eradication on the fate of h. pylori-associated gastric polyp

Conditions: Gastric Polyp; Helicobacter Pylori Infection

Summary: evaluation of the effect of h. pylori eradication on regression of h. pylori-related gastric polyp (ranomized controlled trial) 1. study design: open labeled rct 2. study group h. pylori eradication group (n=17), non-eradication group (n=15) 3. treatment plan 1. baseline egd : 0.3-1cm sized polyp - bx \& clo test (antrum \& body) ==\> if h. pylori positive and eligible patients, randomization 2. triple therapy 3. ubt (4week after eradication) 4. follow-up egd: gross finding, clo test 4. evaluation of polyp regression 1. disappear 2. regression over 50% (size, number) 3. no change or increase (size, number)

(a) study population 1. inclusion hp-realetd polyp polyp size with 0.3cm-1cm 20 yr - 70yr 2. exclusion peptic ulcer, healing stage or acute stage recent use of ppi within 4weeks liver cirrhosis, renal insufficiency, other serious chronic or acute disease current infection of other bacteria, virus, or fungus cancer, psychologic disease heavy drinker drug abuser pregnant women, penicillin allergy, digoxin, antifungal, wafarin previosu h. pylori eradication enroll gastric polyp with bleeding or malignant transformation tiny polyp less than 3mm. (b) study method 1. study design: open labeled rct 2. study group h. pylori eradication group (n=17), non-eradication group (n=15) 3. treatment plan 1. baseline egd: 0.3-1cm sized polyp - bx \& clo test (antrum \& body) ==\> if h. pylori positive and eligible patients, randomization 2. triple therapy 3. ubt (4week after eradication) if eradication failure in triple therapy, 2nd line treatment (metroniazole based quadraple therpay) and the ubt (4week after eradication) 4. follow-up egd (3-9m): gross finding, clo test 4. evaluation of polyp regression 1. disappear 2. regression over 50% (size, number) 3. no change or increase (size, number) 5. statistical analysis 1. chi-square test to compare polyp regression between treatment \& control group. 2. t-test to compare continuous variables between treatment \& control group. 3. paired t-test to compare the size between baseline and follow-up egd. 4. regression analysis: univariate \& multivariate analysis.

Eligibility criteria:
inclusion criteria: * gastric polyp with current infection of h. pylori * gastric polyp size with 3mm-10mm * age of 20 yr - 70yr exclusion criteria: * gastric ulcer ir duodenal ulcer (healing stage or acute stage) * use of ppi within 4weeks * liver cirrhosis, renal insufficiency, other serious chronic or acute disease * current infection of other bacteria, virus, or fungus * any cancer, psychologic disease * heavy drinker * drug abuser * pregnant women * penicillin allergy * use of digoxin, antifungal, wafarin * previous h. pylori eradication * gastric polyp with bleeding or malignant transformation * tiny polyp less than 3mm.

Keywords: gastric polyp helicobacter pylori eradication
bioequivalence study of two imiquimod cream 5%

Conditions: Actinic Keratosis

Summary: the primary objectives are to establish the therapeutic equivalence of imiquimod cream 5%, manufactured by taro pharmaceuticals inc. and aldara (imiquimod) cream, manufactured by 3m, and to show superiority over vehicle in the treatment of ak. the secondary objective is to compare the adverse event (ae) profiles of the two creams.


Eligibility criteria:
inclusion criteria: * patients must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic ak lesions within a 25 cm2 contiguous treatment area on either the face or balding scalp * women either must be 1 year post-menopausal, surgically sterile, or agree to use a medically accepted form or birth control * free of any systemic or dermatological disorder * any skin type or race, providing the skin pigmentation will allow discernment of erythema exclusion criteria: * basal cell or squamous cell carcinoma, or other possible confounding skin conditions (on face and scalp) * history of cutaneous hyperreactivity or facial irritation to topical products * engaging in activities involving excessive or prolonged exposure to sunlight * receiving systemic cancer chemotherapy, psoralen plus uva therapy, uvb therapy, laser abrasion, dermabrasion, glycolic acids, or chemical peels 6 months prior to study entry * currently using or have used systemic steroids 2 months prior to study * currently using or have used on the treatment area over-the-counter retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic keratosis treatments 28 days prior to randomization * pregnant or nursing mothers * history of allergy or sensitivity to imiquimod or related compounds or other components of the formulation * taking immunosuppressant medication

Keywords: actinic keratosis
novel therapeutic approach for human t-cell malignancies

Conditions: T-Cell Leukemia/Lymphoma, Adult

Summary: this multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic t cells by modulating intracellular ros levels. interactions between drugs capable of activating the apoptotic process (e.g., venetoclax) and drugs capable of altering ros homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined. the most promising compounds will be selected based on results obtained in vitro on cell lines and pdx already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory t-cell neoplasms.


Eligibility criteria:
inclusion criteria: * patients with pre- and post-thymic t-cell leukemia/lymphoma * patients of both sexes * age of patients older than 18 years * patient is willing to provide written and signed informed consent for participation in the study exclusion criteria: -serious illness or medical condition that does not allow the patient to be managed according to standard treatment protocols, including uncontrolled active infection.

Keywords: t-cell lymphoblastic leukemias (t-all) t-cell non-hodgkin's lymphomas (t-nhl) nk cell neoplasia ros apoptosis